Insider Shareholders with Direct Ownership of Zentalis Pharmaceuticals, Inc. (ZNTL)
This section provides a comprehensive overview of the insiders with direct ownership of Zentalis Pharmaceuticals, Inc. (ZNTL). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Zentalis Pharmaceuticals, Inc. Insider List
Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
---|---|---|---|---|---|
Anthony Y Sun
President & CEO |
95,069 | 1,190,160 | 1,175,589 $3.48 Million | 38 |
Apr 05, 2022
Reduced 0.21%
|
Kevin D. Bunker
Chief Scientific Officer |
182,935 | 526,213 | 834,931 $2.47 Million | 23 |
Dec 20, 2023
Reduced 2.81%
|
Cam Gallagher
President, Interim CFO |
494,212 | 497,463 | 633,680 $1.88 Million | 52 |
May 31, 2024
Reduced 1.49%
|
Kimberly Blackwell
Chief Executive Officer |
508,800 | 24,655 | 484,145 $1.43 Million | 13 |
Feb 01, 2024
Reduced 4.09%
|
Epperly Melissa B,
Chief Financial Officer |
287,973 | 116,103 | 451,449 $1.34 Million | 27 |
Feb 12, 2024
Reduced 0.57%
|
Diana Hausman
Chief Medical Officer |
377,232 | 3,356 | 373,876 $1.11 Million | 3 |
May 09, 2024
Reduced 0.89%
|
Mark Lackner
Chief Scientific Officer |
181,000 | 1,585 | 195,728 $579,354 | 3 |
Feb 02, 2024
Reduced 0.8%
|
David Michael Johnson
Director |
118,359 | 38,689 | 192,818 $570,741 | 9 |
Jun 21, 2024
Added 20.07%
|
Andrea Paul
Chief Legal Officer |
153,283 | 3,310 | 149,973 $443,920 | 3 |
Feb 02, 2024
Reduced 2.16%
|
Carrie Brownstein
Chief Medical Officer |
116,313 | 10,628 | 105,685 $312,827 | 3 |
Oct 04, 2023
Reduced 1.6%
|
Jan Skvarka
Director |
94,551 | 5,000 | 89,551 $265,070 | 4 |
Jun 21, 2024
Added 31.71%
|
Enoch Kariuki
Director |
79,762 | 0 | 79,762 $236,095 | 3 |
Jun 21, 2024
Added 34.27%
|
Luke Nathaniel Walker
Director |
72,481 | 0 | 72,481 $214,543 | 1 |
May 24, 2024
Added 50.0%
|
Iris Roth
Chief Operating Officer |
52,500 | 0 | 52,500 $155,400 | 1 |
Mar 01, 2023
Added 50.0%
|
Alexis Pinto
Chief Legal Officer |
52,655 | 30,691 | 22,240 $65,830 | 5 |
Feb 14, 2022
Reduced 0.35%
|
Dimitris Voliotis
SVP, Clinical Development |
46,579 | 30,601 | 15,978 $47,294 | 9 |
Feb 14, 2022
Reduced 0.42%
|
Recurium Equity, Llc
> 10% Shareholder |
0 | 4,147,940 | 14,990 $44,370 | 1 |
Oct 28, 2020
Reduced 99.64%
|